The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

1. Rodríguez, P.C.
2. Prada, D.M.
3. Moreno, E.
4. Aira, L.E.
5. Molinero, C.
6. López, A.M.
7. Gómez, J.A.
8. Hernández, I.M.
9. Martínez, J.P.
10. Reyes, Y.
11. Milera, J.M.
12. Hernández, M.V.
13. Torres, R.
14. Avila, Y.
15. Barrese, Y.
16. Viada, C.
17. Montero, E.
18. Hernández, P.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1111/CEI.13061 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus